- tech360.tv
AstraZeneca Teams Up with Immunai in AI Collaboration to Enhance Cancer Drug Trials
AstraZeneca and Immunai Inc have agreed to collaborate on AI-driven cancer drug trials worth US$18 million. Immunai's experience with single-cell genomics and machine learning will be used to decode the immune system. The collaboration will aim to improve clinical decision-making processes in cancer drug trials.
The collaboration aims to use Immunai's AI model of the immune system to speed up specific cancer drug trials. This initiative represents AstraZeneca's ongoing commitment to using artificial intelligence in drug discovery and development, building on previous collaborations such as the $247 million deal with Absci for cancer-fighting antibodies.
Immunai, founded in 2018, specialises in single-cell genomics and machine learning to decode the immune system, thereby facilitating the development of novel therapeutics. The collaboration with AstraZeneca will primarily aim to improve clinical decision-making processes, such as dose selection and biomarker identification, using Immunai's platform. AstraZeneca retains the option of extending the collaboration's duration and scope beyond the initial phase.
By gaining access to Immunai's AI platform, AstraZeneca hopes to gain valuable insights into the mechanisms of action of immunotherapies. Iker Huerga, AstraZeneca's chief data scientist for oncology research and development, emphasised the collaboration's potential to improve understanding of immunotherapeutic approaches in cancer treatment.
AstraZeneca partners with Immunai Inc in an $18 million collaboration for AI-driven cancer drug trials.
Immunai's expertise in single-cell genomics and machine learning will be utilised to decode the immune system.
The collaboration will focus on improving clinical decision-making processes in cancer drug trials.
Source: REUTERS